^
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
No biomarker
|
Thyroid Gland Hurthle Cell Carcinoma
|
denosumab Sensitive: A2 - Guideline
|
denosumab Sensitive: A2 - Guideline
|
RET fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
RET fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
selpercatinib Sensitive: A2 - Guideline
|
selpercatinib Sensitive: A2 - Guideline
|
RET fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
RET fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
pralsetinib Sensitive: A2 - Guideline
|
pralsetinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK3 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK3 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK2 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
NTRK1 fusion
|
Thyroid Gland Hurthle Cell Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
